| Pharmaceutical Information |
| Drug Name |
Halobetasol |
| Drug ID |
BADD_D01051 |
| Description |
Ulobetasol is a highly potent corticosteroid.[A215597] It is structurally related to [clobetasol].[A215597] Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses.[L15047,L15052,L15102]
Ulobetasol was granted FDA approval on 17 December 1990.[L15047] |
| Indications and Usage |
Ulobetasol cream and ointment are indicated in the treatment of inflammatory and pruritic corticosteroid responsive dermatoses.[L15047] Ulobetasol lotion is indicated in the treatment of plaque psoriasis.[L15052] |
| Marketing Status |
approved |
| ATC Code |
D07AC21 |
| DrugBank ID |
DB00596
|
| KEGG ID |
D08660
|
| MeSH ID |
C064466
|
| PubChem ID |
5311167
|
| TTD Drug ID |
D00XPC
|
| NDC Product Code |
Not Available |
| UNII |
9P6159HM7T
|
| Synonyms |
halobetasol | ulobetasol | Ultravate | halobetasol propionate | 6 alpha-fluoroclobetasol 17-propionate | 6-fluoroclobetasol 17-propionate | CGP 14 458 | CGP-14458 | CGP 14458 |
|
| Chemical Information |
| Molecular Formula |
C22H27ClF2O4 |
| CAS Registry Number |
98651-66-2 |
| SMILES |
CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)F)C)F |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
